Beicheng Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4213070/publications.pdf

Version: 2024-02-01

172457 133252 3,755 60 29 59 citations h-index g-index papers 60 60 60 6795 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Obesity, inflammation, and liver cancer. Journal of Hepatology, 2012, 56, 704-713.	3.7	428
2	Obesity and Cancer: The Oil that Feeds the Flame. Cell Metabolism, 2016, 23, 48-62.	16.2	296
3	The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nature Communications, 2017, 8, 15129.	12.8	271
4	Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology, 2011, 54, 900-909.	7.3	260
5	IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation. Journal of Immunology, 2013, 191, 1835-1844.	0.8	256
6	TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 731-741.	3.7	193
7	IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer, 2013, 13, 59.	2.6	157
8	Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death and Disease, 2018, 9, 478.	6.3	122
9	The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. Journal of Hepatology, 2020, 72, 167-182.	3.7	116
10	Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget, 2017, 8, 60149-60158.	1.8	110
11	14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating TÂlymphocytes. Cell Death and Disease, 2018, 9, 159.	6.3	96
12	Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2016, 40, 707-715.	1.6	84
13	Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cellular and Molecular Immunology, 2018, 15, 388-398.	10.5	81
14	Inflammation and liver tumorigenesis. Frontiers of Medicine, 2013, 7, 242-254.	3.4	78
15	Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology, 2013, 57, 678-688.	7.3	74
16	miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males. Clinical Cancer Research, 2011, 17, 5593-5603.	7.0	72
17	RORγt+IL-17+ neutrophils play a critical role in hepatic ischemia–reperfusion injury. Journal of Molecular Cell Biology, 2013, 5, 143-146.	3.3	62
18	High expression levels of IKKÎ \pm and IKKÎ 2 are necessary for the malignant properties of liver cancer. International Journal of Cancer, 2010, 126, 1263-1274.	5.1	58

#	Article	IF	CITATIONS
19	CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein–Coupled Receptor–Mediated Signaling in Hepatocellular Carcinoma. Hepatology, 2018, 68, 1865-1878.	7.3	55
20	IL-22 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1290, 81-88.	1.6	52
21	Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes the Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma via Metastatic Tumor Antigen 1 and Mechanistic Target of Rapamycin Signaling Induction. Journal of Virology, 2014, 88, 11872-11885.	3.4	48
22	Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine, 2021, 66, 103290.	6.1	47
23	The Minimal Set of Genetic Alterations Required for Conversion of Primary Human Fibroblasts to Cancer Cells in the Subrenal Capsule Assay. Neoplasia, 2005, 7, 585-593.	5.3	42
24	Progressive Loss of Malignant Behavior in Telomerase-Negative Tumorigenic Adrenocortical Cells and Restoration of Tumorigenicity by Human Telomerase Reverse Transcriptase. Cancer Research, 2004, 64, 6144-6151.	0.9	40
25	The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity, 2021, 54, 1168-1185.e8.	14.3	40
26	Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. Oncotarget, 2015, 6, 633-641.	1.8	38
27	The cancer-testis IncRNA Inc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nature Cancer, 2022, 3, 203-218.	13.2	38
28	ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. Journal of Hepatology, 2020, 72, 976-989.	3.7	36
29	Inhibition of MTA1 by $\mathrm{ER\hat{l}}\pm$ contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis. Journal of Experimental and Clinical Cancer Research, 2015, 34, 128.	8.6	34
30	Long noncoding RNA GMAN promotes hepatocellular carcinoma progression by interacting with elF4B. Cancer Letters, 2020, 473, 1-12.	7.2	31
31	PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-κB. Journal of Hepatology, 2014, 60, 306-312.	3.7	30
32	Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. Mayo Clinic Proceedings, 2015, 90, 1187-1195.	3.0	30
33	The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends in Pharmacological Sciences, 2014, 35, 349-357.	8.7	28
34	PTPRO-Associated Hepatic Stellate Cell Activation Plays a Critical Role in Liver Fibrosis. Cellular Physiology and Biochemistry, 2015, 35, 885-898.	1.6	28
35	PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. Oncotarget, 2015, 6, 9420-9433.	1.8	27
36	TGF- \hat{l}^2 Signaling Is Often Attenuated during Hepatotumorigenesis, but Is Retained for the Malignancy of Hepatocellular Carcinoma Cells. PLoS ONE, 2013, 8, e63436.	2.5	24

#	Article	IF	CITATIONS
37	PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis. Theranostics, 2020, 10, 5290-5304.	10.0	22
38	Survival and Inflammation Promotion Effect of PTPRO in Fulminant Hepatitis Is Associated with NF-κB Activation. Journal of Immunology, 2014, 193, 5161-5170.	0.8	21
39	<p>lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway</p> . Cancer Management and Research, 2020, Volume 12, 5395-5408.	1.9	21
40	Late onset of severe graftâ€versusâ€host disease following liver transplantation. Transplant Immunology, 2006, 16, 250-253.	1.2	20
41	Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma. Tumor Biology, 2014, 35, 10267-10273.	1.8	19
42	Immortal ALT+ Human Cells Do Not Require Telomerase Reverse Transcriptase for Malignant Transformation. Cancer Research, 2005, 65, 6512-6515.	0.9	18
43	Hydrodynamics-based transfection of plasmid encoding receptor activator for nuclear factor kappa B-Fc protects against hepatic ischemia/reperfusion injury in mice. Liver Transplantation, 2010, 16, 611-620.	2.4	15
44	S100A4 hypomethylation affects epithelial-mesenchymal transition partially induced by LMP2A in nasopharyngeal carcinoma. Molecular Carcinogenesis, 2016, 55, 1467-1476.	2.7	15
45	Differences in the prognostic value of tumor size on hepatocellular cancerâ€specific survival stratified by gender in a SEER populationâ€based study. United European Gastroenterology Journal, 2019, 7, 933-941.	3.8	13
46	Engineered EGCGâ€Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. Advanced Science, 2022, 9, e2105894.	11.2	13
47	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends in Pharmacological Sciences, 2017, 38, 1041-1051.	8.7	12
48	Laennec's approach for laparoscopic anatomic hepatectomy based on Laennec's capsule. BMC Gastroenterology, 2019, 19, 194.	2.0	12
49	ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6â€mediated Lysine 6â€linked polyubiquitination of ASK1 in hepatocytes. Journal of Cellular and Molecular Medicine, 2020, 24, 7814-7828.	3.6	12
50	PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma. Journal of Molecular Cell Biology, 2015, 7, 338-350.	3.3	11
51	Successful adult-to-adult liver transplantation of an otherwise discarded partial liver allograft with a cavernous hemangioma: new strategy for expanding liver donor pool. Transplant International, 2013, 26, e79-e80.	1.6	10
52	Guanine nucleotide–binding protein G(i)α2 aggravates hepatic ischemiaâ€reperfusion injury in mice by regulating MLK3 signaling. FASEB Journal, 2019, 33, 7049-7060.	0.5	10
53	IL-33/ST2 signaling in liver transplantation. Cellular and Molecular Immunology, 2021, 18, 761-763.	10.5	6
54	The level of oncogene H-Ras correlates with tumorigenicity and malignancy. Cell Cycle, 2008, 7, 934-939.	2.6	5

#	Article	IF	CITATIONS
55	Reply. Hepatology, 2014, 59, 1208-1208.	7.3	5
56	Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor. Medicine (United States), 2017, 96, e7295.	1.0	5
57	Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor. Phytomedicine, 2021, 80, 153388.	5.3	3
58	Dorsal approach with Glissonian approach for laparoscopic right anatomic liver resections. BMC Gastroenterology, 2021, 21, 138.	2.0	3
59	A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. Frontiers in Oncology, 2021, 11, 766072.	2.8	2
60	Liver Transplantation Using Right Lobe Graft With Focal Nodular Hyperplasia: Report of 2 Cases. Transplantation Proceedings, 2019, 51, 3347-3350.	0.6	0